MA43169B1 - Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma - Google Patents
Composés héterocycliques en tant qu' inhibiteurs pi3k-gammaInfo
- Publication number
- MA43169B1 MA43169B1 MA43169A MA43169A MA43169B1 MA 43169 B1 MA43169 B1 MA 43169B1 MA 43169 A MA43169 A MA 43169A MA 43169 A MA43169 A MA 43169A MA 43169 B1 MA43169 B1 MA 43169B1
- Authority
- MA
- Morocco
- Prior art keywords
- pi3k
- heterocyclic compounds
- gamma inhibitors
- inhibitors
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La présente invention concerne des composés de formule (i), ou des sels ou stéréoisomères de ceux-ci pharmaceutiquement acceptables, qui sont des inhibiteurs de pi3k-?, utiles pour le traitement de troubles tels que des maladies auto-immunes, le cancer, des maladies cardiovasculaires et des maladies neurodégénératives.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252050P | 2015-11-06 | 2015-11-06 | |
PCT/US2016/060468 WO2017079519A1 (fr) | 2015-11-06 | 2016-11-04 | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43169A MA43169A (fr) | 2018-09-12 |
MA43169B1 true MA43169B1 (fr) | 2022-05-31 |
Family
ID=57460598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43169A MA43169B1 (fr) | 2015-11-06 | 2016-11-04 | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma |
Country Status (17)
Country | Link |
---|---|
US (4) | US10065963B2 (fr) |
EP (2) | EP4086259A1 (fr) |
JP (1) | JP6854817B2 (fr) |
AR (1) | AR106595A1 (fr) |
DK (1) | DK3371190T3 (fr) |
ES (1) | ES2915550T3 (fr) |
HR (1) | HRP20220599T1 (fr) |
HU (1) | HUE059324T2 (fr) |
LT (1) | LT3371190T (fr) |
MA (1) | MA43169B1 (fr) |
MD (1) | MD3371190T2 (fr) |
PL (1) | PL3371190T3 (fr) |
PT (1) | PT3371190T (fr) |
RS (1) | RS63359B1 (fr) |
SI (1) | SI3371190T1 (fr) |
TW (2) | TWI744256B (fr) |
WO (1) | WO2017079519A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
EP3215509B1 (fr) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux |
CN107001379B (zh) | 2014-11-06 | 2022-11-01 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
WO2016130501A1 (fr) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Composés aza-hétéroaryle en tant qu'inhibiteurs de pi3k-gamma |
TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017144633A1 (fr) * | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Inhibiteurs de glycosidases |
BR112018070586A8 (pt) | 2016-04-06 | 2023-04-11 | Lysosomal Therapeutics Inc | Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
CA3020310A1 (fr) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Composes pyrrolo[1,2-a]pyrimidinyl carboxamide et leur utilisation dans le traitement de troubles medicaux |
EP3452481A4 (fr) | 2016-05-05 | 2020-02-26 | Lysosomal Therapeutics Inc. | Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
WO2017223414A1 (fr) | 2016-06-24 | 2017-12-28 | Incyte Corporation | Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y |
SG11202003428VA (en) | 2017-10-18 | 2020-05-28 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
WO2019120212A1 (fr) * | 2017-12-19 | 2019-06-27 | 基石药业(苏州)有限公司 | Inhibiteur d'ido |
CR20210165A (es) | 2018-09-05 | 2021-10-01 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico |
EA202192625A1 (ru) | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
CA3131856A1 (fr) * | 2019-04-11 | 2020-10-15 | Janssen Pharmaceutica N.V. | Cycles pyridine contenant des derives servant d'inhibiteurs de malt1 |
EP3980406A4 (fr) * | 2019-06-06 | 2023-06-28 | Aligos Therapeutics, Inc. | Composés hétérocycliques |
IL292785A (en) * | 2019-11-08 | 2022-07-01 | Ventyx Biosciences Inc | tyk2 pseudokinase ligands |
WO2022228302A1 (fr) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Composés carboxamides hétéroaromatiques et leur utilisation |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
CN1321628C (zh) | 2000-06-28 | 2007-06-20 | 史密斯克莱·比奇曼公司 | 湿磨方法 |
DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
EP1599474B1 (fr) | 2003-03-04 | 2013-04-24 | California Institute Of Technology | Composés oligomères hétérocycliques pour reconnaissance d'ADN |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005118580A2 (fr) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique |
AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
CA2617557A1 (fr) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Derives de benzimidazole en tant que modulateur du sirtuin |
EP1928237A4 (fr) | 2005-09-02 | 2011-03-09 | Abbott Lab | Nouveaux heterocycles a base imidazo |
HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
US20090131481A1 (en) | 2007-03-27 | 2009-05-21 | Paratek Pharmaceuticals, Inc. | Transcription Factor Modulating Compounds and Methods of Use Thereof |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
EP2234486A4 (fr) | 2007-12-19 | 2011-09-14 | Scripps Research Inst | Benzimidazoles et analogues comme inhibiteurs de la rho-kinase |
EP2240023A4 (fr) | 2008-01-15 | 2010-12-29 | Siga Technologies Inc | Médicaments antiviraux pour le traitement d'une infection par un arénavirus |
WO2009133127A1 (fr) | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Composés bicycliques fusionnés et utilisations de ceux-ci comme inhibiteurs de p13k |
WO2009158118A2 (fr) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Agents antibactériens produits à partir d'échafaudages benzo[d]hétérocycliques utilisés pour prévenir et traiter une bactérie multirésistante aux antibiotiques |
US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
TW201028399A (en) | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
EP2401273A1 (fr) | 2009-02-27 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Inhibiteurs tricycliques de pyrazolopyridine kinase |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011075643A1 (fr) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k |
WO2011075630A1 (fr) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Dérivés substitués d'aryles et d'hétéroaryles fusionnés au titre d'inhibiteurs de pi3k |
WO2011099832A2 (fr) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
EP2552208A4 (fr) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | Imidazolyl-imidazoles en tant qu'inhibiteurs de kinase |
EP2558463A1 (fr) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Dérivés condensés en tant qu'inhibiteurs de i3 |
EP2575866A4 (fr) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | Inhibiteurs de ns5a du vhc |
EP2627650A2 (fr) | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | Inhibiteurs n-phénylimidazolecarboxamides de la protéine kinase 3-phosphoinositide-dépendante de type 1 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
EP2627181A4 (fr) | 2010-10-13 | 2014-03-19 | Millennium Pharm Inc | Hétéroaryles et utilisations de ceux-ci |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
WO2012125629A1 (fr) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
WO2012135009A1 (fr) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k |
US9029389B2 (en) * | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
US9212169B2 (en) | 2012-03-01 | 2015-12-15 | Hyogo College Of Medicine | Benzimidazole derivative and use thereof |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JP6217629B2 (ja) | 2012-05-31 | 2017-10-25 | 住友化学株式会社 | 縮合複素環化合物 |
ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
WO2014149207A2 (fr) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Compositions insecticides à base de benzimidazole et procédés apparentés |
EP2976077A4 (fr) | 2013-03-22 | 2016-11-30 | Scripps Research Inst | Benzimidazoles substitués en tant que modulateurs d'un récepteur de nociceptine |
US9394254B2 (en) | 2013-05-08 | 2016-07-19 | The University of Denver and Regis University | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase |
PE20160126A1 (es) | 2013-05-17 | 2016-02-24 | Incyte Corp | Derivados del bipirazol como inhibidores jak |
EP4219477A1 (fr) | 2013-07-17 | 2023-08-02 | Otsuka Pharmaceutical Co., Ltd. | Composés cyanotriazole |
US9751888B2 (en) * | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20220066179A (ko) | 2014-04-08 | 2022-05-23 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
EP2930048A1 (fr) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Dispositif d'affichage tête haute projetant des informations visuelles sur un écran |
WO2015191677A1 (fr) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k |
EA201790502A1 (ru) | 2014-09-16 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновых диметилаз |
US9708348B2 (en) * | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
WO2016130501A1 (fr) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Composés aza-hétéroaryle en tant qu'inhibiteurs de pi3k-gamma |
TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017223414A1 (fr) | 2016-06-24 | 2017-12-28 | Incyte Corporation | Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y |
-
2016
- 2016-11-04 TW TW105136055A patent/TWI744256B/zh active
- 2016-11-04 AR ARP160103370A patent/AR106595A1/es unknown
- 2016-11-04 EP EP22162035.4A patent/EP4086259A1/fr not_active Withdrawn
- 2016-11-04 JP JP2018523015A patent/JP6854817B2/ja active Active
- 2016-11-04 RS RS20220521A patent/RS63359B1/sr unknown
- 2016-11-04 SI SI201631549T patent/SI3371190T1/sl unknown
- 2016-11-04 WO PCT/US2016/060468 patent/WO2017079519A1/fr active Application Filing
- 2016-11-04 LT LTEPPCT/US2016/060468T patent/LT3371190T/lt unknown
- 2016-11-04 ES ES16805238T patent/ES2915550T3/es active Active
- 2016-11-04 DK DK16805238.9T patent/DK3371190T3/da active
- 2016-11-04 PL PL16805238.9T patent/PL3371190T3/pl unknown
- 2016-11-04 PT PT168052389T patent/PT3371190T/pt unknown
- 2016-11-04 TW TW110136698A patent/TWI824309B/zh active
- 2016-11-04 HR HRP20220599TT patent/HRP20220599T1/hr unknown
- 2016-11-04 MA MA43169A patent/MA43169B1/fr unknown
- 2016-11-04 MD MDE20180887T patent/MD3371190T2/ro unknown
- 2016-11-04 EP EP16805238.9A patent/EP3371190B1/fr active Active
- 2016-11-04 US US15/343,375 patent/US10065963B2/en active Active
- 2016-11-04 HU HUE16805238A patent/HUE059324T2/hu unknown
-
2018
- 2018-07-25 US US16/045,358 patent/US10472368B2/en active Active
-
2019
- 2019-10-01 US US16/589,523 patent/US11091491B2/en active Active
-
2021
- 2021-06-24 US US17/356,984 patent/US11773102B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HRP20220599T1 (hr) | 2022-06-24 |
LT3371190T (lt) | 2022-08-10 |
AR106595A1 (es) | 2018-01-31 |
PT3371190T (pt) | 2022-07-08 |
JP2018532760A (ja) | 2018-11-08 |
RS63359B1 (sr) | 2022-07-29 |
US20190062336A1 (en) | 2019-02-28 |
HUE059324T2 (hu) | 2022-11-28 |
TW201726679A (zh) | 2017-08-01 |
MA43169A (fr) | 2018-09-12 |
DK3371190T3 (da) | 2022-05-23 |
TWI744256B (zh) | 2021-11-01 |
EP4086259A1 (fr) | 2022-11-09 |
US10472368B2 (en) | 2019-11-12 |
US11773102B2 (en) | 2023-10-03 |
US10065963B2 (en) | 2018-09-04 |
US11091491B2 (en) | 2021-08-17 |
US20200031837A1 (en) | 2020-01-30 |
US20230009843A1 (en) | 2023-01-12 |
MD3371190T2 (ro) | 2022-09-30 |
TW202204362A (zh) | 2022-02-01 |
JP6854817B2 (ja) | 2021-04-07 |
SI3371190T1 (sl) | 2022-08-31 |
EP3371190A1 (fr) | 2018-09-12 |
WO2017079519A1 (fr) | 2017-05-11 |
PL3371190T3 (pl) | 2022-11-07 |
EP3371190B1 (fr) | 2022-03-30 |
TWI824309B (zh) | 2023-12-01 |
ES2915550T3 (es) | 2022-06-23 |
US20170129899A1 (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
MA54133B1 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
MA50398B1 (fr) | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma | |
MA41977B1 (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
MA44656A (fr) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1 | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
PH12021550743A1 (en) | Boron containing pde4 inhibitors | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
PH12021550258A1 (en) | Cdk8/19 inhibitors | |
MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam |